$GL

Kalmbach Thomas Peter sold $1.2M of GL

Kalmbach Thomas Peter (EVP & CFO) sold 7,936 shares of GLOBE LIFE INC. (GL) at $156.59 ($1.24M total) on 2026-05-22.

Original reporting
SEC EDGAR · Kalmbach Thomas Peter
Published May 26, 2026, 5:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 5:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GL
Bearish
medium confidence
Mentioned
$GL
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GLBearishMed
01

Why it matters

The disclosure can influence short-term sentiment and options/flow positioning, but it does not provide new fundamentals or corporate actions.

02

Market read

Traders may treat this as a modest negative signal for GL sentiment, while awaiting any corroborating fundamental news.

03

What to watch

No 10b5-1 plan is cited, which can increase interpretive uncertainty; traders may also compare with prior insider activity frequency and size to gauge whether this is isolated.

Relevance 7/10Timing: Immediate (filed today); any price reaction typically fades quickly unless accompanied by other news.

Background

SEC Form 4 discloses insider transactions; this filing reports an open-market sale by Globe Life’s EVP & CFO.

Company-level read

Ticker impact

$GLBearishMedium confidence
Context

Globe Life CFO sold 7,936 shares in an open-market transaction for about $1.24M, per SEC Form 4 filed 2026-05-26.

Expected impact

Likely modest, short-lived negative bias; follow-through depends on whether selling is part of routine diversification or a broader trend.

Evidence & confidence

The article is limited to an SEC Form 4 sale (no 10b5-1 plan stated) and does not include earnings, M&A, or operational updates.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide regulatory or competitive shock.

None indicated; Globe Life is a US-listed insurer and the filing does not reference macro/regional events.

Low; no international transaction or cross-border catalyst mentioned.

Counterpoint

The sale may reflect routine personal liquidity needs or tax planning rather than a bearish view, especially since the filing lacks any stated performance or outlook rationale.

Key entities

  • Globe Life Inc.

    Subject of the insider transaction disclosure: EVP & CFO Kalmbach sold 7,936 shares for ~$1.24M.

  • Kalmbach Thomas Peter

    EVP & CFO who executed the open-market sale; holdings after transaction were 50,496 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GLMedAI 8/10

Globe Life Boosts EPS Outlook Following Strong Q2 Earnings

Globe Life Inc. reported Q2 net income of $288 million, or $3.65 per share, up 20% year over year, and net operating income of $285 million, or $3.61 per share, up 10%. The insurer cited underwriting strength and excess investment returns and raised full-year guidance to 2026 net operating EPS of $15.55-$15.95 and share repurchases of $670M-$700M.

$GLMed

Why Globe Life (GL) Shares Are Sliding Today

Globe Life (NYSE: GL) shares fell about 7% after its Q2 results met Wall Street estimates but did not provide upside. Revenue rose 6.7% to about $1.6B and net premiums earned were about $1.30B. GAAP EPS was $3.65 vs $3.64 expected. The stock closed at $170.96.

$GLMedAI 8/10

Globe Life Q2 Earnings Call Highlights

Globe Life (NYSE:GL) reported Q2 health premium revenue up 16% to $437M and health underwriting margin up 1% to $99M, though the margin fell to about 23%. Life policy obligations improved. Management raised 2026 net operating EPS guidance to $15.55 to $15.95 and increased buybacks. The company repurchased ~1.1M shares for $175M in Q2.

$GLMedAI 8/10

Why is Globe Life stock sliding today? By Investing.com

Globe Life shares fell 8.1% after its Q2 2026 results. Net operating income was $3.61 per diluted share versus $3.67 consensus, while revenue was $1.60B versus $1.59B. Full-year 2026 EPS guidance was raised to $15.55-$15.95 but the midpoint ($15.75) stayed below $15.65 consensus, alongside insider net selling and a risk-off market.